Serialization Capabilities Now Operational at Lonza Edinburgh Facility for Liquid-Filled Hard Capsules
News Dec 15, 2017
Lonza announced that its integrated development and manufacturing site for biopharmaceutical liquid-filled hard capsules in Edinburgh (UK) has new anti-counterfeiting security capabilities in place and is in full compliance with EU and U.S. regulatory requirements for serialization. Lonza’s customers will benefit from this investment to secure the integrity of sales packs now and in the future.
With increasing threats to patient safety from counterfeited and diverted pharmaceuticals, regulatory mandates for serialization in more than 40 countries are being implemented to secure the world’s pharmaceutical supply chain. Serialization – also known as track-and-trace – refers to country- or region-specific systems used to track the passage of pharmaceuticals through the supply chain and into the marketplace.
According to the World Health Organization, an estimated 7-15 percent of all medicines sold in developed countries are falsified – either contaminated or containing the wrong active or the right active in the wrong dose – and up to 40 percent of medicines in developing countries are counterfeit.
The EU Falsified Medicines Directive (FMD) Safety Features Delegated Regulation dictates that all licensed drug products must be serialized from early 2019. Similarly, serialization will be officially required in the United States from November 2018 in line with the U.S. Drug Supply Chain Security Act (DSCSA).
“It’s important for our customers to know that our Lonza Edinburgh facility is ahead of the curve and already fully compliant with the new regulatory requirements in the United States and EU to combat anti-counterfeiting,” said Jane Fraser, PhD, Site Head at Lonza’s Edinburgh facility. "Our new serialization line and quality system – fully commissioned and qualified this year – are now being used to serialize our customers’ sales packs, well in advance of the serialization deadlines."
The requirements of serialization and product tracking (SPT) mandates vary by country or legislative region. However, every region is implementing compliance reporting systems that oblige pharmaceutical companies to provide the regulators a mix of master data, packaging and serialization information or supply chain transaction events, among others.
The implementation of these anti-counterfeit technologies is the most extensive preventive measure used by government authorities to help guarantee a secure supply chain worldwide.
“Lonza is committed to providing exceptional quality and service to our customers," said Gordon Bates, Head of Chemical Division, Lonza. "Our investment in serialization and product-tracking capability, which is now online, reflects Lonza's ongoing commitment to respond to the needs of our customers and to protect patients.”
Lonza’s Serialization Processes
Lonza’s new serialization line will serialize and tamper-proof liquid-filled hard-capsule (LFHC) sales packs (cartons) and will aggregate cartons to shippers and shippers to pallets. The system utilizes ©Optel Group Ltd. technology and has been designed to meet the varied requirements across all key countries and regions. The system also serves to complement the site’s capabilities in supplying commercial market-ready packaging (blisters, leaflets, cartons, shippers) for its customers.
Specifically, these five new processes are in place to combat counterfeiting schemes and protect the security of supply of Lonza’s LFHC products:
1. Sales Pack (Carton) Printing and Inspection
Cartons will be printed by thermal inkjet with fully traceable unique identifier serialization coding and human readable text. All cartons are 100 percent inspected for quality of print, and all packs that are below the required standard are 100 percent rejected
2. Shipper to pallet aggregation
The system will aggregate the sales pack to the shipper and associate the shippers to the pallet
3. Post Batch Rework
Serialization data provides allowance for damaged and sampled drug product within a serialized batch
4. Receiving Serialization Codes
The system is capable of receiving serialization codes from customers’ systems via a secure server
5. Data Storage and Communications
The system will securely store serialization and aggregation data and communicate this information back to the customer’s server, for communication with the central hub
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Shaken and Stirred: Scaling Up Bioreactors’ Fluid DynamicsNews
By applying analytical techniques often reserved for large-scale industrial bioreactors to smaller lab-based counterparts, researchers are bridging the gap between different ways of mixing biomaterials.READ MORE